Invivyd, Inc. (NASDAQ:IVVD) Director Sells $30,718.73 in Stock

Invivyd, Inc. (NASDAQ:IVVD) Director Terrance Mcguire sold 65,359 shares of Invivyd stock in a transaction on Monday, December 16th. The stock was sold at an average price of $0.47, for a total value of $30,718.73. Following the completion of the sale, the director now directly owns 4,012,320 shares of the company’s stock, valued at approximately $1,885,790.40. The trade was a 1.60 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Terrance Mcguire also recently made the following trade(s):

• On Wednesday, December 11th, Terrance Mcguire sold 160,400 shares of Invivyd stock. The shares were sold at an average price of $0.59, for a total value of $94,636.00.
• On Monday, December 9th, Terrance Mcguire sold 150,000 shares of Invivyd stock. The shares were sold at an average price of $0.61, for a total transaction of $91,500.00.

Invivyd Trading Down 9.3 %

Shares of IVVD opened at $0.44 on Thursday. The company has a market capitalization of $53.18 million, a PE ratio of -0.23 and a beta of 0.53. Invivyd, Inc. has a 12-month low of $0.44 and a 12-month high of $5.20. The business’s 50 day moving average is $0.80 and its 200 day moving average is $1.03.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on IVVD. Morgan Stanley cut their price target on Invivyd from $9.50 to $3.55 and set an “overweight” rating for the company in a research note on Wednesday, November 20th. EF Hutton Acquisition Co. I upgraded shares of Invivyd to a “strong-buy” rating in a research report on Wednesday, October 30th. HC Wainwright reduced their price objective on Invivyd from $15.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday, November 20th. Finally, D. Boral Capital reiterated a “buy” rating and set a $9.00 target price on shares of Invivyd in a research report on Thursday, November 21st. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $7.89.

Hedge Funds Weigh In On Invivyd

Several institutional investors have recently bought and sold shares of IVVD. SG Americas Securities LLC boosted its stake in Invivyd by 198.6% during the second quarter. SG Americas Securities LLC now owns 37,893 shares of the company’s stock valued at $42,000 after buying an additional 25,201 shares during the last quarter. Bank of New York Mellon Corp bought a new stake in shares of Invivyd in the 2nd quarter worth about $263,000. Rhumbline Advisers lifted its holdings in shares of Invivyd by 4,434.1% in the 2nd quarter. Rhumbline Advisers now owns 84,017 shares of the company’s stock valued at $92,000 after acquiring an additional 82,164 shares during the last quarter. Acadian Asset Management LLC grew its position in Invivyd by 232.0% in the second quarter. Acadian Asset Management LLC now owns 678,706 shares of the company’s stock worth $745,000 after acquiring an additional 474,301 shares in the last quarter. Finally, Cornercap Investment Counsel Inc. bought a new stake in Invivyd during the second quarter worth approximately $86,000. 70.36% of the stock is owned by hedge funds and other institutional investors.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.